Cite
Graier T, Weger W, Sator PG, et al. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD Int. 2020;2:62-75doi: 10.1016/j.jdin.2020.10.012.
Graier, T., Weger, W., Sator, P. G., Salmhofer, W., Gruber, B., Jonak, C., Kölli, C., Schütz-Bergmayr, M., Vujic, I., Ratzinger, G., Häring, N., Painsi, C., Prillinger, K., Mlynek, A., Skvara, H., Trattner, H., Tanew, A., Lichem, R., Ellersdorfer, C., Legat, F., Gruber-Wackernagel, A., Hofer, A., Schmiedberger, E., Hoetzenecker, W., Müllegger, R., Saxinger, W., Quehenberger, F., & Wolf, P. (2021). Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD international, 262-75. https://doi.org/10.1016/j.jdin.2020.10.012
Graier, Thomas, et al. "Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis." JAAD international vol. 2 (2021): 62-75. doi: https://doi.org/10.1016/j.jdin.2020.10.012
Graier T, Weger W, Sator PG, Salmhofer W, Gruber B, Jonak C, Kölli C, Schütz-Bergmayr M, Vujic I, Ratzinger G, Häring N, Painsi C, Prillinger K, Mlynek A, Skvara H, Trattner H, Tanew A, Lichem R, Ellersdorfer C, Legat F, Gruber-Wackernagel A, Hofer A, Schmiedberger E, Hoetzenecker W, Müllegger R, Saxinger W, Quehenberger F, Wolf P. Effectiveness and clinical predictors of drug survival in psoriasis patients receiving apremilast: A registry analysis. JAAD Int. 2020 Dec 26;2:62-75. doi: 10.1016/j.jdin.2020.10.012. eCollection 2021 Mar. PMID: 34409355; PMCID: PMC8362309.
Copy
Download .nbib